EUVIMEDEUVIMED entdecken
Open Access

Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy

Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Kan Kishibe, Shunsuke Yasuda, Yuki Yajima, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Shohei Harabuchi, Michihisa Kono und 9 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03394-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Toshihiro Nagato und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan. rijun@asahikawa-med.ac.jp. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Lymphoma, T-Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The engagement of CD27 on lymphocytes with its ligand, CD70, on tumors is believed to mediate tumor immune evasion and the elevation of serum soluble CD27 (sCD27) levels in patients with CD70-positive malignancies. We previously showed that CD70 is expressed in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), an Epstein-Barr virus (EBV)-related malignancy. However, little is known about serum sCD27 expression and its association with the clinical characteristics of, and the CD27/CD70 interaction in, ENKL. In the present study, we show that serum sCD27 is significantly elevated in the sera of patients with ENKL. The levels of serum sCD27 provided excellent diagnostic accuracy for discriminating patients with ENKL from healthy subjects, correlated positively with the levels of other diagnostic markers (lactate dehydrogenase, soluble interleukin-2 receptor, and EBV-DNA), and decreased significantly following treatment. Elevated serum sCD27 levels also correlated significantly with advanced clinical stage and tended to correspond with shorter survival, in patients with ENKL. Immunohistochemistry indicated that CD27-positive tumor-infiltrating immune cells exist adjacent to CD70-positive lymphoma cells. In addition, serum sCD27 levels in patients with CD70-positive ENKL were significantly higher than those in patients with CD70-negative ENKL, suggesting that the intra-tumoral CD27/CD70 interaction boosts the release of sCD27 in serum. Furthermore, the EBV-encoded oncoprotein latent membrane protein 1 upregulated CD70 expression in ENKL cells. Our results suggest that sCD27 may serve as a novel diagnostic biomarker and also may serve as a tool for evaluating the applicability of CD27/CD70-targeted therapies by predicting intra-tumoral CD70 expression and CD27/CD70 interaction in ENKL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsLymphoma, T-CellHumansCD27 LigandHerpesvirus 4, HumanBiomarkersKiller Cells, NaturalTumor Necrosis Factor Receptor Superfamily, Member 7

Stichwörter der Autor:innen

CD27CD70Extranodal NK/T-cell lymphomaImmunotherapySoluble form

Substanzen

CD27 LigandBiomarkersTumor Necrosis Factor Receptor Superfamily, Member 7CD70 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan. rijun@asahikawa-med.ac.jp.
  • Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan.
  • Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
  • Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Nagato, T., Komatsuda, H., Hayashi, R., Takahara, M., Kishibe, K., Yasuda, S., Yajima, Y., Kosaka, A., Ohkuri, T., Oikawa, K., Harabuchi, S., Kono, M., Yamaki, H., Wakisaka, R., Hirata-Nozaki, Y., Ohara, K., Kumai, T., Katada, A., Hayashi, T., …, & Kobayashi, H. (2023). Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03394-7

Vancouver

Nagato T, Komatsuda H, Hayashi R, Takahara M, Kishibe K, Yasuda S, et al. Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03394-7

BibTeX
@article{Nagato2023,
  author = {Nagato, Toshihiro and Komatsuda, Hiroki and Hayashi, Ryusuke and Takahara, Miki and Kishibe, Kan and Yasuda, Shunsuke and Yajima, Yuki and Kosaka, Akemi and Ohkuri, Takayuki and Oikawa, Kensuke and Harabuchi, Shohei and Kono, Michihisa and Yamaki, Hidekiyo and Wakisaka, Risa and Hirata-Nozaki, Yui and Ohara, Kenzo and Kumai, Takumi and Katada, Akihiro and Hayashi, Tatsuya and Harabuchi, Yasuaki and Kobayashi, Hiroya},
  title = {Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03394-7}
}
Kostenlos starten →